title: [Nilotinib treatment for imatinib resistant or intolerant chronic myelogenous leukemia.].
authors.affiliation: Department of Hematology, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200025, China.
authors.forename: Ai-Hua
authors.initials: AH
authors.lastname: Wang
authors.forename: Li
authors.initials: L
authors.lastname: Zhou
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: You
authors.forename: Li
authors.initials: L
authors.lastname: Wang
authors.forename: Jun-Min
authors.initials: JM
authors.lastname: Li
authors.forename: Jiong
authors.initials: J
authors.lastname: Hu
authors.forename: Zhi-Xiang
authors.initials: ZX
authors.lastname: Shen
mesh_terms: D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D016044:Fusion Proteins, bcr-abl; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D010879:Piperazines / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl